Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 1/20 | 0.49 |
| ▸ | F10 | P00742 | 1/20 | 0.49 |
| ▸ | PLAU | P00749 | 1/20 | 0.49 |
| ▸ | PLAT | P00750 | 1/20 | 0.49 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.49 |
| ▸ | HPN | P05981 | 1/20 | 0.49 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.49 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.49 |
| ▸ | F7 | P08709 | 1/20 | 0.49 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 7/20 | 0.48 |
| ▸ | PRKAG1 | P54619 | 4/20 | 0.46 |
| ▸ | PRKAA2 | P54646 | 4/20 | 0.46 |
| ▸ | PRKAB1 | Q9Y478 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | PRKAB2 | O43741 | 3/20 | 0.43 |
| ▸ | PRKAA1 | Q13131 | 3/20 | 0.43 |
| ▸ | PRKAG3 | Q9UGI9 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL988050 | 0.84 | RAB9A (0.59) | F7FFAR1KDM4ERAB9AALDH1A1 | |
| SCHEMBL27437769 | 0.81 | KDR (0.56) | FFAR1KDM4ERAB9AALDH1A1POLB | |
| SCHEMBL11438464 | 0.78 | POLB (0.50) | FFAR1KDM4ERAB9AALDH1A1POLB | |
| SCHEMBL5788066 | 0.77 | GRIK1 (0.54) | F2F10PLAUPLATKLKB1 | |
| SCHEMBL25175575 | 0.75 | KDM4E (0.62) | KDM4ERAB9AALDH1A1POLB | |
| SCHEMBL26086683 | 0.74 | F3 (0.50) | F2F10PRSS1PRSS2PRSS3 | |
| SCHEMBL26089405 | 0.74 | SLC22A12 (0.48) | F2F10PRSS1PRSS2PRSS3 | |
| SCHEMBL6438204 | 0.74 | SIGMAR1 (0.47) | KDM4EALDH1A1POLB | |
| SCHEMBL10412899 | 0.74 | NPC1 (0.66) | F2F10PLAUPLATKLKB1 | |
| SCHEMBL17351250 | 0.73 | KDM4E (0.43) | PRKAG1PRKAA2PRKAB1KDM4ERAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1042316-B1 | INDOLE DERIVATIVES USEFUL A.O. FOR THE TREATMENT OF OSTEOPOROSIS | NIKEM RESEARCH SRL (IT) | 2005-02-09 | — | — | EP | disclosed |
| US-6506758-B2 | 4-(5,6-dichloro-1H-indol-2-yl)-N-(1,2,2,6,6-pentamethyl -piperidin-4-yl)benzamide, for example; selective for mammalian osteoclasts, acting to selectively inhibit their bone resorbing activity | SMITHKLINE BEECHAM LABORATOIRES PHARMCEUTIQUES (FR) | 2003-01-14 | — | — | US | disclosed |
| US-20020099080-A1 | Indole derivatives useful A.O. for the treatment of osteoporosis | SMITHKLINE BEECHAM LABORATOIRES PHARMACEUTIQUES | 2002-07-25 | — | — | US | disclosed |
| EP-1042316-A1 | INDOLE DERIVATIVES USEFUL A.O. FOR THE TREATMENT OF OSTEOPOROSIS | SMITHKLINE BEECHAM LABORATOIRES PHARMACEUTIQUES (FR) | 2000-10-11 | — | — | EP | disclosed |
| WO-1999033822-A1 | INDOLE DERIVATIVES USEFUL A.O. FOR THE TREATMENT OF OSTEOPOROSIS | SMITHKLINE BEECHAM LABORATOIRES PHARMACEUTIQUES (FR) | 1999-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099080-A1 | Indole derivatives useful A.O. for the treatment of osteoporosis | SOST, NR3C2, EBP | F2 3006/4885F10 2988/4885PLAU 4642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.